Predicting how well biologics work for IBD
Part of Digestive system clinical trials.
This study builds a model to predict which biologic drug will work best for people with active inflammatory bowel disease (IBD). It uses data from patients already treated with biologics to help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of IBD (Crohn's disease or ulcerative colitis).
- Your IBD must be in an active, symptomatic phase.
- You must have received at least one biologic treatment since your diagnosis.
- You must have follow-up test results showing how well the biologic worked for you.
- You cannot have another autoimmune disease that also requires biologic treatment.
- You cannot have serious conditions like cancer or a hole in your intestine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
This study looks at how well different biologic medications work for people with moderate to severe ulcerative colitis or Crohn's disease after one year of treatment. The goal is to see which treatment helps the gut heal best.
This study looks at why some people with inflammatory bowel disease (Crohn's or ulcerative colitis) do not respond to certain biologic treatments. Researchers will use advanced testing (multi-omics) to better understand treatment response. If you are starting or have just started treatment with infliximab, adalimumab, vedolizumab, or ustekinumab, you may be able to join.
This study looks at what factors help predict how inflammatory bowel disease (IBD) may progress over time. You may be able to join if you are an adult with IBD and fit one of the study groups based on whether you have used TNF-blocking medicines before.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study uses an intestinal ultrasound and fat measurements to see if they can predict how well biologic therapies will work for people with active ulcerative colitis. The goal is to find better ways to choose treatment.
Hear when a new Inflamatory Bowel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.